Celebrex contains celecoxib, which reduces the production of inflammatory substances involved in pain and swelling. It is prescribed for adults with osteoarthritis, rheumatoid arthritis, or selected…
Celebrex contains celecoxib, which reduces the production of inflammatory substances involved in pain and swelling. It is prescribed for adults with osteoarthritis, rheumatoid arthritis, or selected acute pain conditions. Its COX-2 selectivity can reduce inflammation while producing less direct stomach irritation than some traditional NSAIDs, though cardiovascular, kidney, and gastrointestinal risks remain relevant.
Celebrex is a prescription nonsteroidal anti-inflammatory drug (NSAID) containing celecoxib. It belongs to the coxib group, which selectively inhibits cyclooxygenase-2, or COX-2. Celecoxib is used to reduce pain, stiffness, and inflammation in adults with osteoarthritis, rheumatoid arthritis, and certain acute pain conditions.
Celebrex contains celecoxib, a prescription nonsteroidal anti-inflammatory drug (NSAID) in the selective COX-2 inhibitor group. It is supplied as oral capsules.
Celecoxib is used in adults for:
Osteoarthritis involves gradual changes in joint cartilage and surrounding tissues. Rheumatoid arthritis is an autoimmune inflammatory disease that can affect multiple joints and organs. Celebrex can ease symptoms, but it does not reverse cartilage damage or cure the underlying autoimmune process.
Celebrex is not suitable for you if you:
Important interactions include:
Pregnancy requires special care. NSAIDs can affect fetal circulation and kidney function later in pregnancy, and exposure near delivery can increase complications. Celecoxib should only be considered during pregnancy when the prescriber has assessed the balance of benefit and risk. Breastfeeding also requires a medication review.
The most frequently reported reactions include indigestion, abdominal discomfort, diarrhoea, nausea, headache, dizziness, and swelling caused by fluid retention. Some people develop raised blood pressure. Mild symptoms can settle, but persistent or worsening symptoms need clinical review.
Celecoxib can also produce serious reactions:
The risk of cardiovascular events can increase with dose and duration. Celecoxib should not be used for pain after coronary artery bypass graft surgery. The EMA product information also addresses cardiovascular, gastrointestinal, renal, hepatic, and hypersensitivity risks [2].
A practical detail is easy to miss: ankle swelling may be mistaken for a minor joint problem. New swelling in both legs, rapid weight gain, or breathlessness can indicate fluid retention and needs prompt assessment.
Celecoxib blocks the COX-2 enzyme, reducing the formation of prostaglandins. Prostaglandins are signalling chemicals that contribute to pain sensitivity, inflammation, and raised temperature. The FDA prescribing information describes celecoxib as a selective COX-2 inhibitor at therapeutic doses [1].
COX-1 and COX-2 are related enzymes, but they have different roles. COX-1 helps support normal stomach protection, platelet activity, and kidney blood flow. COX-2 becomes more active during many inflammatory processes. Celecoxib targets COX-2 more strongly than COX-1, while traditional NSAIDs usually inhibit both enzymes to a greater degree.
This mechanism explains both the potential benefit and the limitations:
The pharmacological sequence is:
Several routine mistakes reduce benefit or increase harm:
Celebrex, ibuprofen, naproxen, and meloxicam all belong to the NSAID family, but their enzyme selectivity and dosing patterns differ. Aspirin has additional antiplatelet effects at low doses, so it should not be treated as interchangeable with celecoxib.
| Medicine or group | Main pharmacological profile | Typical clinical pattern |
|---|---|---|
| Celebrex — celecoxib | Relatively selective COX-2 inhibition | Often taken once or twice daily, depending on indication and prescribed dose |
| Ibuprofen or naproxen | Broader COX-1 and COX-2 inhibition | Usually requires repeated daily dosing for ongoing symptoms |
| Meloxicam | Preferential COX-2 activity at lower doses, with less selectivity than celecoxib | Commonly used once daily, subject to the prescribed regimen |
These patterns are general pharmacological comparisons, not instructions to substitute one product for another. The best choice depends on gastrointestinal history, blood pressure, kidney function, heart disease, other medicines, and the reason for treatment.
The NICE osteoarthritis guideline advises using the lowest effective NSAID dose for the shortest suitable duration, with attention to gastrointestinal protection and individual risk factors [3]. Celebrex may be useful for people who need anti-inflammatory treatment and have a clinical reason to avoid a less selective NSAID. It can still cause ulcers, bleeding, fluid retention, kidney injury, and cardiovascular complications.
Celecoxib’s COX-2 selectivity may produce fewer endoscopic stomach ulcers than some non-selective NSAIDs in selected patients. That difference does not mean that Celebrex cannot cause indigestion, ulceration, or gastrointestinal bleeding. Risk rises with older age, previous ulcer disease, corticosteroid use, anticoagulants, antiplatelet medicines, and longer treatment.
A proton-pump inhibitor may be prescribed for gastrointestinal protection when the risk profile warrants it.
This is a separate medicine and does not cancel the cardiovascular or kidney risks associated with NSAID treatment.
In clinical practice, prescribers often view Celebrex as a risk-stratified NSAID rather than a universally safer painkiller. Its COX-2 selectivity can be useful when gastrointestinal risk is a concern, yet cardiovascular and renal assessment remains essential.
A doctor will usually aim for the lowest dose that controls symptoms for the shortest suitable period. Chronic osteoarthritis may require intermittent treatment, physiotherapy, weight-management support, or other non-drug measures. Rheumatoid arthritis normally needs disease-modifying antirheumatic therapy, because an NSAID alone does not prevent joint damage.
Blood pressure and kidney function become more relevant when treatment continues, when the person is older, or when diuretics and renin–angiotensin system medicines are also used. A patient who feels better should not automatically continue Celebrex indefinitely without a treatment review.
Stop taking further Celebrex and seek urgent medical help for chest pain, sudden weakness, facial swelling, severe wheezing, vomiting blood, black stools, blistering skin, or a major reduction in urine. The FDA prescribing information from 2023 describes serious cardiovascular, gastrointestinal, kidney, and hypersensitivity reactions associated with NSAIDs. These symptoms require urgent assessment rather than simple dose adjustment.
Take the missed dose when remembered unless the next dose is due soon. When the next scheduled dose is near, skip the missed dose and continue with the normal timetable; do not take two capsules together. NHS medicines guidance published in 2024 gives the same general approach for many prescription medicines, while the individual Celebrex schedule remains determined by the prescriber.
A course may be brief for acute pain or longer for chronic osteoarthritis and rheumatoid arthritis. Long-term treatment can be appropriate for selected patients, but the dose, blood pressure, kidney function, gastrointestinal risk, and cardiovascular history should be reviewed periodically. NICE guidance from 2022 supports using NSAIDs at the lowest suitable dose for the shortest practical duration, with protection against gastrointestinal harm when indicated.
Discuss previous ulcers or gastrointestinal bleeding, heart disease, stroke, high blood pressure, kidney or liver problems, asthma after aspirin or NSAIDs, pregnancy, breastfeeding, and every medicine or supplement being used. Mention warfarin, aspirin, corticosteroids, antidepressants, lithium, methotrexate, diuretics, and blood-pressure medicines specifically. The EMA product information from 2025 highlights these clinical factors when assessing celecoxib treatment.
Active gastrointestinal bleeding, a serious prior allergic reaction to NSAIDs, coronary artery bypass surgery, and severe untreated cardiovascular, kidney, or liver disease can rule out Celebrex. Pregnancy in the third trimester is another clear contraindication because NSAIDs may harm the fetus and complicate delivery. HPRA safety information available in 2025 supports careful screening for these risks before celecoxib is prescribed.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
Based on 3 reviews
After two weeks of prescribed Celebrex for a flare of knee osteoarthritis, I noticed less morning stiffness and could walk farther. I had mild indigestion during the first few days, so I took it with food and reported it at my review.
Two weeks 7 Oct 2026I used Celebrex for acute shoulder pain for a short course. The pain settled enough for sleep, but the effect was not immediate and I still needed physiotherapy. I mistakenly took ibuprofen on one day before checking the combination, so I stopped doing that after the pharmacist explained the risk.
A short course 24 Oct 2026Celebrex helped my rheumatoid arthritis pain, especially in the morning. After several weeks I developed swollen ankles and higher blood pressure, and the doctor changed the plan. It had helped the joints, but continuing it was not suitable for me.
Several weeks 4 Nov 2026
